Abiopharma

🔍 RA CAPITAL MANAGEMENT, L.P. (Executive)

Company: Vor Biopharma Inc. (VOR)

Report Date: 2026-04-02

Detailed Transactions and Holdings:

• Sold 258,475 shares of Common Stock at $18.23 per share (Direct)
  Date: 2026-04-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,146,523.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,525 shares of Common Stock at $19.06 per share (Direct)
  Date: 2026-04-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,144,998.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Sold 537,754 shares of Common Stock at $16.51 per share (Direct)
  Date: 2026-04-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,607,244.00 | transaction_form_type: 4 | Footnotes: F5, F2
• Sold 44,728 shares of Common Stock at $17.31 per share (Direct)
  Date: 2026-04-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,562,516.00 | transaction_form_type: 4 | Footnotes: F6, F2
• Sold 6,775 shares of Common Stock at $18.5 per share (Direct)
  Date: 2026-04-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,555,741.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $19.04 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
• F3: Held directly by the Fund.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.05 to $19.09 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.25 to $17.245 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $18.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• REMARKS: Dr. Andrew Levin, a Partner and Managing Director of the Adviser, serves on the Issuer's board of directors.